Immutep Stock
Immutep Limited
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- CEO
- Marc Voigt
- Employees
- 53
- Market cap
- $24 M
- IPO
- 19/04/2012
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the…
Immutep stock: price history
1D
-0.3%
1W
-11.8%
1M
-51.1%
6M
-72.6%
YTD
-94.4%
1Y
-92.4%
2Y
-92.2%
5Y
-95.9%
10Y
-98.3%
Next earnings date
Next earnings date
25/02/2027 (in 131 days)
Volatility around earnings
~39% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vgolden-cross-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Golden Cross
BullishThe 50-day moving average crossed above the 200-day moving average. This is one of the best-known long-term trend-following signals in technical analysis.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Immutep
Analyst assessment of Immutep
PRICE TARGET LOW
US$3.50
CONSENSUS
US$4.25
MEDIAN
US$4.25
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
2
BUY
2
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 17/06/2026
Immutep stock metrics
P/E
-0.43
P/B
0.55
EV/EBITDA
0.4
RETURN ON EQUITY
-56.8%
NET MARGIN
-328.8%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.1%
FLOAT SHARES
7,151,749
AVG. DAILY VOLUME (30D)
275,772
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Immutep stock
What does Immutep do?
Immutep Limited is a company in the Healthcare sector, Biotechnology industry, headquartered in Australia.
The CEO is Marc Voigt, the company employs around 53 people.
The IPO was on 19/04/2012; the stock trades on NASDAQ under the ticker IMMP.
What do analysts say about Immutep stock?
4 analysts rate the stock, the consensus is Buy (as of 17/06/2026).
The average price target is US$4.25, ranging from US$3.50 to US$5.00, with a median of US$4.25.
This is an external assessment, not a statement by Market Jury.
When does Immutep report next?
The next earnings date is 25/02/2027.
Around past earnings, price swings were roughly -39% stronger than usual.
Does Immutep pay a dividend?
No, Immutep currently does not pay a dividend.
Which stocks are comparable to Immutep?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Immutep stock analyzed?
Clicking "Analyze stock" lets five strategies assess Immutep against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.